AwardTape · Defense awards · Quva Pharma, Inc
Quva Pharma, Inc: -$47K in DoD and DHS awards
Quva Pharma, Inc holds 1 DoD and DHS prime award with -$47K obligated Nov 9, 2023 to Apr 21, 2025. Largest category: Drugs and biologicals at -$47K; largest buyer: Department of the Army at -$47K.
| Obligated FY2024+ | -$47K |
|---|---|
| Awards | 1 |
| FY2024 | $155K |
| FY2025 | -$203K |
| FY2026 to date | $0 |
| Lifetime obligated on these awards | $443K |
| Parent company (as reported) | Quva Pharma Inc |
| First and latest action | Nov 9, 2023 · Apr 21, 2025 |
| # | Category | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Drugs and biologicals | -$47K | 1 awards | 100% |
| # | Agency | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Department of the Army | -$47K | 1 awards | 100% |
| Award | Obligated FY2024+ | What | Agency | Category | Latest action |
|---|---|---|---|---|---|
| W81K0019P0334 purchase order | -$47K | Ropivacaine 0.2% in sodium chloride pf | Army | Drugs and biologicals | Apr 21, 2025 DoD 90d |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Data as of Oct 9, 2026.
Terminal: filters, alerts and CSV export for this company's awards.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial